NCT00059592 is a Phase 1 clinical trial of Valacyclovir in Shingles, sponsored by Baylor College of Medicine.

Who is sponsoring NCT00059592?

NCT00059592 is sponsored by Baylor College of Medicine.

What drugs are being tested in NCT00059592?

Interventions in NCT00059592: Valacyclovir.

What condition does NCT00059592 study?

NCT00059592 studies Shingles, Bone Marrow Transplantation.

Is NCT00059592 still recruiting?

NCT00059592 is currently completed. Last updated 4 March 2020.

Last reviewed 2020-03-04 · How we verify

NCT00059592

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Valacyclovir in Immunocompromised Children

Completed Phase 1 Last updated 4 March 2020

What this trial tests

Phase 1 trial testing Valacyclovir in Shingles in 37 participants. Completed in 5 May 2005.

Timeline

7 April 1998

Primary endpoint
30 December 2004

5 May 2005

Quick facts

Lead sponsor	Baylor College of Medicine
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	37
Start date	7 April 1998
Primary completion	30 December 2004
Estimated completion	5 May 2005
Sites	2 locations across United States

Drugs / interventions tested

Valacyclovir — full drug profile →

Conditions studied

Shingles — all drugs for Shingles →
Bone Marrow Transplantation — all drugs for Bone Marrow Transplantation →

Sponsor

Baylor College of Medicine

Who can join

Adults 2 to 18, any sex, with Shingles or Bone Marrow Transplantation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Shingles is an infection commonly seen in children with a weakened immune system (immunocompromised children). The immune system can be weakened as a result of medications that patients receive for cancer or other serious illness or as a result of a bone marrow transplantation. Shingles in children with a weakened immune system may spread throughout the body and in some instances may be life-threatening. Acyclovir is a medication that is routinely used to treat immunocompromised children with shingles in order to prevent further spread of their shingles and to help them heal faster. Acyclovir is also given to bone marrow transplant patients to prevent reactivation of HSV infection. Valacyclovir is a new drug that is metabolized (broken down in the body) to acyclovir. Valacyclovir is given by mouth and studies done in adults have shown it to be more effective than acyclovir given by mouth. The purpose of this study is to * study the pharmacology of this drug (how the body handles this drug), * determine if oral Valacyclovir can be safely given to children with shingles, and * determine the type of side effects that occur when oral Valacyclovir is given to immunocompromised children.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Valacyclovir

Trials testing the same drug.

NCT06914479 — Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and · Phase 1 · recruiting
NCT07014397 — Effect of Valaciclovir on Inter-Appointment Pain in Endodontic Treatment of Necrotic Teeth · NA · completed
NCT05468619 — Neonatal Phase 1 Valacyclovir Study · Phase 1 · completed
NCT05536349 — Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chroni · Phase 2 · recruiting
NCT05492591 — A Study Exploring Efficacy of Peginterferon in Patients With Herpes Zoster · Phase 2 · completed

Other recruiting trials for Shingles

Currently open trials in the same condition.

NCT05554068 — Immunogenicity of Zoster Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients · Phase 2 · recruiting
NCT05596526 — Immunogenicity of the Recombinant Zoster Vaccine in Multiple Sclerosis Patients · Phase 4 · recruiting
NCT05304351 — Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older · Phase 2 · active not recruiting

Other Baylor College of Medicine trials

Trials by the same sponsor.

NCT07513194 — GPC3 CAR T Cells With IL-15 and IL-21 for Recurrent ATRT and CNS Rhabdoid Tumors (RADIANT) · Phase 1 · not yet recruiting
NCT05855824 — Toddler Biomarker of Nutrition Study · NA · not yet recruiting
NCT06738628 — Disposable Endoscope Platform in Third Space Endoscopic Procedures · not yet recruiting
NCT06834997 — Dronabinol As an Adjunct for Reducing Pain (DARP)-Texas Children's Hospital · Phase 2 · withdrawn
NCT07387614 — WEB-BASED SUPPORT PROGRAM FOR CAREGIVERS OF VETERANS WITH DEMENTIA DISCHARGED FROM SKILLED NURSING FACILITIES TO HOME · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00059592 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Baylor College of Medicine
Last refreshed: 4 March 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00059592.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing